65-47-4 (胞苷-5'-三磷酸,Cytidine-5'-triphosphate)

5'-三磷酸胞苷;胞苷-5’-三磷酸;胞苷-5'-三磷酸;

Cytidine 5'-(tetrahydrogen triphosphate);5'-CYTIDYLATE TRIPHOSPHATE;CTP;5'-cytidylate triphosphate (CTP);CYTIDINE 5'-TRIPHOSPHATE;cytidine triphosphate-Na2;cytidine-5'-triphosphate;cytidinetriphosphate;cytosine-5'-triphosphate;H4ctp;Cytidine 5'-triphosphoric acid;Rubella E1 envelope protein;DB02431;Cytidine 3'-triphosphate;CHEMBL223533;HY-125818;Cytidine, mono(tetrahydrogen triphosphate) (ester);Brain-1 protein, mouse;GTPL1741;1wvc;[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (hydroxy-phosphonooxyphosphoryl) hydrogen phosphate;147258-10-4;Cytidine triphosphate;EINECS 200-611-4;2ad5;bmse000277;[[(2R,3S,4R,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate;((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate;ARA-CYTIDINE TRIPHOSPHATE;({[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid;2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-D-ribofuranosyl]-;BRN 0071190;SCHEMBL104629;65-47-4;[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;CHEBI:17677;5'-CTP;CYTIDINE-5/'-TRIPHOSPHATE DISODIUM SALT;A805056;CYTIDINE, 5'-(TETRAHYDROGEN TRIPHOSPHATE);F82425;5 inverted exclamation marka-CTP pound not3Na;123334-07-6;C00063;Cytidine 5' Triphosphate;CS-0100072;K0118UX80T;[[[(2R,3S,4R,5R)-5-(4-Amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid;Cytidine 5'-(tetrahydrogen triphosphate) (8CI,9CI);Cytidine5'-(tetrahydrogentriphosphate);5'-(tetrahydrogen triphosphate) cytidine;CYTIDINE TRIPHOSPHATE [WHO-DD];Cytidine mono;Q409648;UNII-K0118UX80T;Cytidine 5-Prime-Triphosphate;Cytidine mono(tetrahydrogen triphosphate) (ester);Cystetine Triphosphate;BDBM50454133;AKOS016843990;Deoxycytosine triphosphate;disodium [[[5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-oxido-phosphoryl] hydrogen phosphate;Cytidine-5'-triphosphoric acid disodium salt;4-25-00-03676 (Beilstein Handbook Reference);131016-01-8;DTXSID70889324;Cytidine-5'-(tetrahydrogen triphosphate);SCHEMBL25201848;81012-87-5;PCDQPRRSZKQHHS-XVFCMESISA-N;

MFCD00047493

PCDQPRRSZKQHHS-XVFCMESISA-N

1S/C9H16N3O14P3/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1

P(=O)(O)(OP(=O)(O)OP(=O)(O)O)OC[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(C=C2)N)=O)O1)O)O

200-611-4

适用于脂肪肝、脑神经疾患及动脉粥样硬化等的辅助治疗。

以CTP为原料发酵法发酵、除蛋白 取磷酸二氢钾6.5kg，加适量水溶解，加氯化镁0.6kg,葡萄糖17.5kg，搅拌使其溶解，取CMP2.5kg加水溶解，用****调pH=7，加水至70L，搅拌下加热至50-60℃，加入酵母液180L，保持30-32℃ 3h，反应终点加盐酸调pH=5，停止反应。加三氯乙酸，调pH=2.5，离心，得清液。CMP[酵母]→[30-32℃, 3h]发酵液[三氯乙酸]→[pH2.5]上清液去盐、沉淀、纯化 将清液加入强酸性苯乙烯系阳离子交换树脂 (001×7)，搅拌吸附15min，使pH为1.5-1.7，静置30min，过滤，滤液加乙醇至醇的浓度为75%，静置过夜，过滤，滤饼加水溶解使浓度为25%，再加五分之一滤饼体积的硅藻土，搅拌过滤，收集滤液。上清液[001×7树脂]→[pH1.5-1.7, 15min]滤液[乙醇]→[8h]沉淀物[水，硅藻土]→[搅拌，过滤]滤液吸附、洗脱、脱色 取滤液加水稀释成0.5%-0.6%的溶液，调Ph=2-2.5，用强碱性季铵I型阴离子交换树脂(717)吸附后，先用水洗涤8h，再用pH 2的0.03mol/L的氯化钠溶液洗脱ADP.在波长280nm处溶液吸光度大于0.4时，改用pH2的水洗涤4h，最后用pH2的1mol/L氯化钠溶液洗脱ATP，洗脱液加入千分之一量的活性炭，搅拌，脱色，过滤，收集滤液。滤液[717树脂]→[pH2-2.5]吸附物[氯化钠]→[pH2]洗脱[活性炭]→[40min]滤液沉淀、干燥 滤液调Ph=3-5，加3倍量乙醇，静置，过滤，用无水乙醇和无水乙醚洗涤滤饼，真空干燥，即是三磷酸胞苷二钠。滤液[乙醇]→[pH3.5]沉淀物[无水乙醇，无水乙醚]→三磷酸胞苷二钠。